The meaning of antipsychotic medication to patients with schizophrenia

Journal of Psychiatric Practice

Volumn 18, Issue 5, 2012, Pages 338-348

  Seeman, Mary V ^a   Seeman, Neil ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; TRIFLUOPERAZINE;

ACNE; AMBIVALENCE; AMENORRHEA; CLINICAL DECISION MAKING; CONSENSUS; CULTURAL FACTOR; DOCTOR PATIENT RELATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG LABELING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIC DISORDER; GALACTORRHEA; GYNECOMASTIA; HIRSUTISM; HUMAN; MENTAL HEALTH; MENTAL HEALTH SERVICE; NEGATIVE SYNDROME; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SOCIAL INTERACTION; SOCIAL LIFE; STIGMA; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; SCHIZOPHRENIA;

EID: 84866845567     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000419818.60505.95     Document Type: Review

References (78)

1. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive view of recent literature. J Clin Psychiatry 2002;63:892-909.
2. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60.
3. Nordentoft M. Prevention of suicide and attempted suicide in Denmark: Epidemiological studies and intervention studies in selected risk groups. Dan Med Bull 2007;54: 306-69.
4. Glick RA, Roose SP. Talking about medication. J Am Psychoanal Assoc 2006;54:745-62.
5. Irani F, Dankert M, Siegel SJ. Patient and family attitudes toward schizophrenia treatment. Curr Psychiatry Rep 2004;6:283-8.
6. Pound P, Britten N, Morgan M, et al. Resisting medicines: A synthesis of qualitative studies of medicine taking. Soc Sci Med 2005:61:133-55.
7. Britten N, Riley R, Morgan M. Resisting psychotropic medicines: A synthesis of qualitative studies of medicinetaking. Adv Psychiatr Treat 2010;16:207-18.
8. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62:717-24.
9. Rosenfield PJ. Poison or cure: Meanings of medication in schizophrenia. J Am Acad Psychoanal Dyn Psychiatry 2007;35:189-201.
10. Noguchi M. Subjective meaning of taking antipsychotic medication for patients with schizophrenia in Japan. World Cultural Psychiatry Res Rev 2008;3:191-7.
11. Sajatovic M, Jenkins JH. Is antipsychotic medication stigmatizing for people with mental illness? Int Rev Psychiatry 2007;19:107-12.
12. Sartorius N, Gaebel W, Cleveland H-R, et al. WPA guidance on how to combat stigmatization of psychiatry and psychiatrists. World Psychiatry 2010;9:131-44.
13. Bentley KJ. Psychiatric medication and meaning-making in a residential program for adults with serious mental illness. Qual Soc Work 2010;9:479-99.
14. Naudin J, Dassa D, Cermolacce M. La compliance aux antipsychotiques d'action prolongée: D'un probleme d'image à une question d'indication. (Compliance with longacting atypical antipsychotics: From an image problem to a question of indication). Encephale 2009;35:315-20.
15. Jenkins JH, Carpenter-Song EA. Awareness of stigma among persons with schizophrenia: Marking the contexts of lived experience. J Nerv Ment Dis 2009;197:520-9.
16. Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and sideeffects of antidepressants. J Affect Disord 2011;130:290-3.
17. Born K, Rizo C, Seeman N. Participatory storytelling online: A complementary model of patient satisfaction. Healthc Q 2009;12:105-10.
18. Frost JH, Massagli MP. Social uses of personal health information within PatientsLikeMe, an online patient community: What can happen when patients have access to one another's data. J Med Internet Res 2008;10:e15.
19. Wicks P, Massagli M, Frost J, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res 2010;12:e19.
20. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: A content analysis of Internet data. Acta Psychiatr Scand 2009;120:102-11.
21. Cutler DM, Everett W. Thinking outside the pillbox- Medication adherence as a priority for health care reform. N Engl J Med 2010;362:1553-5.
22. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat 2007;13:336-46.
23. Charpentier A, Goudemand M, Thomas P. L'alliance thérapeutique, un enjeu dans la schizophrénie (Thera - peutic alliance, a stake in schizophrenia). Encephale 2007; 35:80-9.
24. Fain DS, Sharon A, Moscovici L, et al. Psychotropic medication from an object relations theory perspective: An analysis of vignettes from group psychotherapy. Int J Group Psychother 2008;58:303-26.
25. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-48.
26. Seeman MV, Cohen R. A service for women with schizophrenia. Psychiatr Serv 1998;49:674-7.
27. Leibing A. Inverting compliance, increasing concerns: Aging, mental health, and caring for a trustful patient. Anthropol Med 2010;17:145-58.
28. Dolovich L, Nair K, Sellors C, et al. Do patients' expecta-tions influence their use of medications? Can Fam Physician 2008;54:384-93.
29. Mendel R, Traut-Mattausch E, Frey D, et al. Do physicians' recommendations pull patients away from their preferred treatment options? Health Expect 2012;15:23-31.
30. Mintz DL. Teaching the prescriber's role: The psychology of psychopharmacology. Acad Psychiatry 2005;29:187-94.
31. Mintz D. Psychodynamic Trojan horses: Using psychopharmacology to teach psychodynamics. J Am Acad Psychoanal Dyn Psychiatry 2006;34:151-61.
32. Mintz D, Belnap B. A view from Riggs: Treatment resistance and patient authority-III. What is psychodynamic psychopharmacology? An approach to pharmacologic treatment resistance. J Am Acad Psychoanal Dyn Psychiatry 2006;34:581-601.
33. Scott J. Cognitive and behavioural approaches to medication adherence. Adv Psychiatr Treatment 1999;5:338-47.
34. Deegan P, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv 2006;57:1636-9.
35. Davidson L, Miller R, Flanagan E. What's in it for me? The utility of psychiatric treatments from the perspective of the person in recovery. Epidemiologia e Psichiatria Sociale 2008;17:177-81.
36. Seeman MV. Schizophrenia symptoms: Normal adaptations to inability. Med Hypoth 2007;69:253-7.
37. Roe D, Swarbrick M. A recovery-oriented approach to psychiatric medication: Guidelines for nurses. J Psychosoc Nurs Ment Health Serv 2007;45:35-40.
38. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79.
39. Blenkiron P. Stories and analogies in cognitive behaviour therapy: A clinical review. Behav Cogn Psychotherapy 2005;33:45-59.
40. Pies RW. Psychiatrists, physicians, and the prescriptive bond. Psychiatric Times, editorial, June 2, 2010 (available at www.psychiatrictimes. com/display/article/10168/1579874, accessed July 23, 2012).
41. Britten N, Stevenson F, Gafaranga J, et al. The expression of aversion to medicines in general practice consultations. Soc Sci Med 2004;59:1495-503.
42. Roe D, Goldblatt H, Baloush-Klienman V, et al. Why and how people decide to stop taking prescribed psychiatric medication: Exploring the subjective process of choice. Psychiatr Rehabil J 2009;33:38-46.
43. Usher K. Taking neuroleptic medicines as the treatment for schizophrenia: A phenomenological study. Austral NZ J Ment Health Nurs 2001;10:145-55.
44. Piat M, Sabetti J, Bloom D. The importance of medication in consumer definitions of recovery from serious mental illness: A qualitative study. Issues Ment Health Nurs 2009;30:482-90.
45. West C. Powerful choices: Peer support and individualized medication self-determination. Schizophr Bull 2011;37: 445-50.
46. Shoemaker SJ, Ramalho de Oliveira D. Understanding the meaning of medications for patients: The medication experience. Pharm World Sci 2008;30:86-91.
47. Novak L, Svab V. Antipsychotics' side effects influence on stigma of mental illness: Focus group study results. Psychiatr Danub 2009;21:99-102.
48. Carrick R, Mitchell A, Powell R, et al. The quest for wellbeing: A qualitative study of the experience of taking antipsychotic medication. Psychol Psychother 2004;77: 19-33.
49. Seeman MV. Antipsychotics and physical attractiveness. Clin Schizophr Relat Psychoses 2011;5:142-6C.
50. Arigo D, Suls JM, Smyth JM. Social comparisons and chronic illness: Research synthesis and clinical implications. Health Psychology Rev January 24, 2012 (DOI: 10.1080/17437199.2011.634572).
51. Kriegshauser K, Sajatovic M, Jenkins JH, et al. Gender differences in subjective experience and treatment of bipolar disorder. J Nerv Ment Dis 2010;198:370-2.
52. Seeman MV. Antipsychotic-induced amenorrhea. J Ment Health 2011;20:484-91.
53. Borras L, Huguelet P, Eytan A. Delusional " pseudotranssexualism" in schizophrenia. Psychiatry 2007;70:175-9.
54. Ahuja N, Moorhead S, Lloyd AJ, et al. Antipsychoticinduced hyperprolactinemia and delusion of pregnancy. Psychosomatics 2008;49:163-7.
55. Seeman MV, Seeman N. Psychopharmacology and motherhood. In: Göpfert M, Webster J, Seeman MV, eds. Parental psychiatric disorder: Distressed parents and their families. Cambridge, UK: Cambridge University Press; 2004: 241-8.
56. Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia. European multicentre randomized controlled trial. Br J Psychiatry 2006;189:508-14.
57. Julius RJ, Novitsky MA, Dubin WR. Medication adherence: A review of the literature and implications for clinical practice. J Psychiatr Pract 2009;15:34-44.
58. Doran E, Robertson J, Henry D. Moral hazard and prescription medicine use in Australia-The patient perspective. Soc Sci Med 2005;60:1437-43.
59. van der Geest S, Hardon A. Social and cultural efficacies of medicines: Complications for antiretroviral therapy. J Ethnobiol Ethnomed 2006;2:48.
60. Li TCW. Psychodynamic aspects of psychopharmacology. J Am Acad Psychoanal Dyn Psychiatry 2010;38:655-74.
61. Saint Arnault D, Kim O. Is there an Asian idiom of distress? Somatic symptoms in female Japanese and Korean students. Arch Psychiatr Nurs 2008;22:27-38.
62. Charles C, Gafni A, Whelan T, et al. Cultural influences on the physician-patient encounter: The case of shared treatment decision-making. Patient Educ Couns 2006;63: 262-7.
63. McKinney KA, Greenfield BG. Self-compliance at "Prozac campus." Anthropol Med 2010;17:173-85.
64. Thorne S, Paterson B, Russell C, et al. Complementary/ alternative medicine in chronic illness as informed selfcare decision making. Intern J Nurs Studies 2002;39: 671-83.
65. Craice MA, Benedetto D, Blasco P, et al. Even a little magic. Can Family Phys 2008;54:1146-7.
66. Khan A, Bomminayuni EP, Bhat A, et al. Are the colors and shapes of current psychotropics designed to maximize the placebo response? Psychopharmacol (Berlin) 2010; 211:113-22.
67. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002;136:471-6.
68. Kirmayer LJ. The cultural diversity of healing: Meaning, metaphor and mechanism. Br Med Bull 2004;69:33-48.
69. van der Geest S, Reynolds Whyte S, Hardon A. The anthropology of pharmaceuticals: A biographical approach. Annual Rev Anthropology 1996;25:153-78.
70. Richard C, Lussier MT. Nature and frequency of exchanges on medications during primary care encounters. Patient Educ Couns 2006;64:207-16.
71. Alfonso CA. Dynamic psychopharmacology and treatment adherence. J Am Acad Psychoanal Dyn Psychiatry 2009; 37:269-86.
72. Happell B, Manias E, Roper C. Wanting to be heard: Mental health consumers' experiences of information about medication. Int J Ment Health Nurs 2004;13:242-8.
73. Rapport FL, Jerzembek GS, Doel MA, et al. Narrating uncertainties about treatment of mental health conditions. Soc Psychiatry Psychiatr Epidem 2010;45:71-9.
74. de Millas W, Lambert M, Naber, D. The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clini Neurosci 2006;8: 131-6.
75. Hamann J, Kruse J, Schmitz FS, et al. Patient participation in antipsychotic drug choice decisions. Psychiatry Res 2010;17:63-7.
76. Hamann J, Mendel R, Reiter S, et al. Why do some patients with schizophrenia want to be engaged in medical decision making and others do not? J Clin Psychiatry 2011;72:1636-43.
77. Mitchell AJ. Adherence behaviour with psychotropic medication is a form of self-medication. Med Hypoth 2007;68: 12-21.
78. Powell AD. The medication life. J Psychother Pract Res 2001;10:217-22.